Skip to main content
Federal & State Lawfederalstatelaw.com
Home/Federal/Bills (Live)
HOUSE 1629117th CongressReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Fairness in Orphan Drug Exclusivity Act

Last Action
5/20/2021

Actions

  • 2021-05-20Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • 2021-05-19Motion to reconsider laid on the table Agreed to without objection.
  • 2021-05-19On passage Passed by the Yeas and Nays: 402 - 23 (Roll no. 150). (text: CR H2561)
  • 2021-05-19Passed/agreed to in House: On passage Passed by the Yeas and Nays: 402 - 23 (Roll no. 150).(text: CR H2561)
  • 2021-05-19Considered as unfinished business. (consideration: CR H2572-2573)
  • 2021-05-19POSTPONED PROCEEDINGS - At the conclusion of debate on H.R. 1629, the Chair put the question on passage and by voice vote, announced that the ayes had prevailed. Mrs. Greene (GA) demanded the yeas and nays and the Chair postponed further proceedings on the question of passage until a time to be announced.
  • 2021-05-19The previous question was ordered pursuant to the rule.
  • 2021-05-19DEBATE - The House proceeded with one hour of debate on H.R. 1629.
  • 2021-05-19Rule provides for consideration of H.R. 1629 and H. Res. 275. The resolution provides for consideration of H.R. 1629 under a closed rule and H. Res. 275 under a closed rule. The resolution provides for one hour of debate on both the bill and resolution. The rule provides that H. Res. 398 is hereby adopted. The rule provides at any time through the legislative day of Thursday, May 20, 2021, the Speaker may entertain motions offered by the Majority Leader or designee with respect to multiple measures that were object of motions to suspend the rules on the legislative days of May 17 or 18, 2021.
  • 2021-05-19Considered under the provisions of rule H. Res. 403. (consideration: CR H2560-2563)
  • 2021-05-17Rules Committee Resolution H. Res. 403 Reported to House. Rule provides for consideration of H.R. 1629 and H. Res. 275. The resolution provides for consideration of H.R. 1629 under a closed rule and H. Res. 275 under a closed rule. The resolution provides for one hour of debate on both the bill and resolution. The rule provides that H. Res. 398 is hereby adopted. The rule provides at any time through the legislative day of Thursday, May 20, 2021, the Speaker may entertain motions offered by the Majority Leader or designee with respect to multiple measures that were object of motions to suspend the rules on the legislative days of May 17 or 18, 2021.
  • 2021-05-11On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 250 - 168 (Roll no. 134).
  • 2021-05-11Failed of passage/not agreed to in House: On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 250 - 168 (Roll no. 134).
  • 2021-05-11Considered as unfinished business. (consideration: CR H2184-2185)
  • 2021-05-11At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2021-05-19 (53)

Fairness in Orphan Drug Exclusivity Act

This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats. The sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.)

Under this bill, if a drug is designated as an orphan drug on the basis that there is no reasonable expectation that the sponsor will recover the costs of developing and distributing the drug from U.S. sales, the drug shall be granted the seven-year exclusivity period only if the sponsor demonstrates that there is no reasonable expectation that it will recover such costs specifically within its first 12 years of U.S. sales of the drug. This requirement shall also apply retroactively to an orphan drug that was granted such an exclusivity period before this bill's enactment.

When deciding whether an orphan drug meets this requirement, the FDA shall consider the sales of all drugs from the sponsor that are covered by the same orphan drug designation.

Cosponsors (2)

  • Marc Veasey (D-TX)
  • Brian Fitzpatrick (R-PA)

Subjects

  • Competition and antitrust
  • Drug safety, medical device, and laboratory regulation
  • Licensing and registrations
  • Marketing and advertising
  • Prescription drugs
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.